MSB Annual Financial Results and Operational Highlights
Filed with ASX · · 8 pages · English
• At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 • Up to an additional US$40 million available from existing facilities subject to certain milestones • Net operating spend of US$65.8 million for the 12 months ended June 2022, a 35% reduction on comparative year, with continued
In the deck
Story so far
Earlier from Mesoblast
- Preliminary Final Report
- US$45 Million Private Placement to Major Shareholders
- Reinstatement to Quotation
- Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
- Third Quarter Results Presentation
Later from Mesoblast
- Submits New Information to FDA IND File for SR-aGVHD
- First Quarter Financial Results on Form 6-K
- MSB Q1 Financial Results and Operational Highlights
- Long-Term Survival for Acute GvHD Treatment with Remestemcel
- Extension of Undrawn US$30 million Facility
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast